JUDICIAL DRUG PRICE ENQUIRY IN ITALY?

10 July 1994

Pharmaceutical prices set by the drug pricing committee in Italy by the former head of the Italian Health Ministry's pharmaceutical services, Duilio Poggiolini (who is presently under arrest; Marketletters passim), may soon be the subject of a judicial enquiry.

No confirmation is yet available, but it is though the state budget controlling body, the Corte dei Conti, may be considering such a move on the grounds of financial damages wrought on Italy's finances. Artificially high price rises for drugs may have weighed unduly heavily on the public health system and on the budget of local health providers. Corte dei Conti sources have said it is probable there will be a judicial investigation, which would have to be initiated through its regional offices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight